A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
← catalyst calendarNCT06842498 · readout in 589 d
Sponsored by Kyntra Bio (industry) · KYNB — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
75estimated
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-22 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-Resistant Prostate Cancer
Intervention
- Drug: FG-3246 — also filed as FOR46
Primary outcomes
what the primary-completion date above is the date OFRadiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria
measured Until radiographic progression is noted (up to approximately 25 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
measured From first dose until 28 days after last dose (up to approximately 25 months)
Maximum Plasma Concentration (Cmax) of FG-3246, Total Anti-cluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE)
measured Within each 21 day treatment cycle from Cycle 1 through 28 days post last dose (up to approximately 25 months)
Permalink · KYNB's whole pipeline · Catalyst calendar · Every registered study · What changed